Reversibility of Diffusion-Weighted Imaging Lesions in Patients With Ischemic Stroke in the WAKE-UP Trial.


Journal

Stroke
ISSN: 1524-4628
Titre abrégé: Stroke
Pays: United States
ID NLM: 0235266

Informations de publication

Date de publication:
06 2023
Historique:
medline: 24 5 2023
pubmed: 9 5 2023
entrez: 9 5 2023
Statut: ppublish

Résumé

Reversibility of the diffusion-weighted imaging (DWI) lesion means that not all of the DWI lesion represents permanently injured tissue. We investigated DWI reversibility and the association with thrombolysis, reperfusion and functional outcome in patients from the WAKE-UP trial (Efficacy and Safety of Magnetic Resonance Imaging-Based Thrombolysis in Wake-Up Stroke). In this retrospective analysis of WAKE-UP, a randomized controlled trial (RCT) between September 2012 and June 2017 in Belgium, Denmark, France, Germany, Spain and United Kingdom, a convolutional neural network segmented the DWI lesions (b=1000 s/mm In 363 patients, the median DWI volume was 3 (1-10) mL at baseline and 6 (2-20) mL at follow-up. Volumetric DWI reversibility was present in 19% (69/363) with a median absolute reversible volume of 1 mL (0-2) or 28% (14-50) relatively. Voxel-based DWI reversibility was present in 358/363 (99%) with a median absolute volume of 1 mL (0-2), or 22% (9-38) relatively. In 18% of the patients (67/363), relative voxel-based DWI reversibility >50% was present. Volumetric DWI reversibility and relative voxel-based DWI reversibility >50% was more frequent in patients treated with alteplase versus placebo (OR, 1.86 [95% CI, 1.09-3.17] and OR, 2.03 [95% CI, 1.18-3.50], respectively). Relative voxel-based DWI reversibility >50% was associated with excellent functional outcome (OR, 2.30 [95% CI, 1.17-4.51]). Small absolute volumes of DWI reversibility were present in a large proportion of randomized patients in the WAKE-UP trial. Reversibility was more often present after thrombolysis.

Sections du résumé

BACKGROUND
Reversibility of the diffusion-weighted imaging (DWI) lesion means that not all of the DWI lesion represents permanently injured tissue. We investigated DWI reversibility and the association with thrombolysis, reperfusion and functional outcome in patients from the WAKE-UP trial (Efficacy and Safety of Magnetic Resonance Imaging-Based Thrombolysis in Wake-Up Stroke).
METHODS
In this retrospective analysis of WAKE-UP, a randomized controlled trial (RCT) between September 2012 and June 2017 in Belgium, Denmark, France, Germany, Spain and United Kingdom, a convolutional neural network segmented the DWI lesions (b=1000 s/mm
RESULTS
In 363 patients, the median DWI volume was 3 (1-10) mL at baseline and 6 (2-20) mL at follow-up. Volumetric DWI reversibility was present in 19% (69/363) with a median absolute reversible volume of 1 mL (0-2) or 28% (14-50) relatively. Voxel-based DWI reversibility was present in 358/363 (99%) with a median absolute volume of 1 mL (0-2), or 22% (9-38) relatively. In 18% of the patients (67/363), relative voxel-based DWI reversibility >50% was present. Volumetric DWI reversibility and relative voxel-based DWI reversibility >50% was more frequent in patients treated with alteplase versus placebo (OR, 1.86 [95% CI, 1.09-3.17] and OR, 2.03 [95% CI, 1.18-3.50], respectively). Relative voxel-based DWI reversibility >50% was associated with excellent functional outcome (OR, 2.30 [95% CI, 1.17-4.51]).
CONCLUSIONS
Small absolute volumes of DWI reversibility were present in a large proportion of randomized patients in the WAKE-UP trial. Reversibility was more often present after thrombolysis.

Identifiants

pubmed: 37158080
doi: 10.1161/STROKEAHA.122.041505
doi:

Substances chimiques

Tissue Plasminogen Activator EC 3.4.21.68

Types de publication

Randomized Controlled Trial Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1560-1568

Auteurs

Lauranne Scheldeman (L)

Department of Neurology, University Hospitals Leuven, Belgium (L.S., A.W., R.L.).
Department of Neurosciences, Experimental Neurology KU Leuven (L.S., A.W., R.L.), University of Leuven, Belgium.
Center for Brain and Disease Research, Laboratory of Neurobiology, VIB, Leuven, Belgium (L.S., A.W., R.L., J.B.).

Anke Wouters (A)

Department of Neurology, University Hospitals Leuven, Belgium (L.S., A.W., R.L.).
Department of Neurosciences, Experimental Neurology KU Leuven (L.S., A.W., R.L.), University of Leuven, Belgium.
Center for Brain and Disease Research, Laboratory of Neurobiology, VIB, Leuven, Belgium (L.S., A.W., R.L., J.B.).
Department of Neurology, Amsterdam University Medical Centers, the Netherlands (A.W.).

Jeroen Bertels (J)

Processing Speech and Images, Department of Electrial Engineering (J.B.), University of Leuven, Belgium.
Center for Brain and Disease Research, Laboratory of Neurobiology, VIB, Leuven, Belgium (L.S., A.W., R.L., J.B.).

Patrick Dupont (P)

Department of Neurosciences, Laboratory for Cognitive Neurology KU Leuven (P.D.), University of Leuven, Belgium.
Leuven Brain Institute, Belgium (P.D.).

Bastian Cheng (B)

Klinik und Poliklinik für Neurologie, Kopf- und Neurozentrum, University Medical Center Hamburg-Eppendorf, Germany (B.C., C.G., G.T.).

Martin Ebinger (M)

Center for Stroke Research Berlin (CSB) Charit. - Universit.tsmedizin Berlin, Germany (M. Ebinger, M. Endres, J.B.F.).
Klinik für Neurologie, Medical Park Berlin Humboldtmühle, Germany (M. Ebinger).

Matthias Endres (M)

Klinik und Hochschulambulanz für Neurologie, Charit. - Universit.tsmedizin Berlin, Germany (M. Endres).
German Center for Cardiovascular Research (DZHK), partner site Berlin (M. Endres).
German Center for Neurodegenerative Diseases (DZNE), partner site Berlin (M. Endres).
ExcellenceCluster NeuroCure (M. Endres).

Jochen B Fiebach (JB)

Center for Stroke Research Berlin (CSB) Charit. - Universit.tsmedizin Berlin, Germany (M. Ebinger, M. Endres, J.B.F.).

Christian Gerloff (C)

Klinik und Poliklinik für Neurologie, Kopf- und Neurozentrum, University Medical Center Hamburg-Eppendorf, Germany (B.C., C.G., G.T.).

Keith W Muir (KW)

School of Psychology & Neuroscience, University of Glasgow, United Kingdom (K.W.M.).

Norbert Nighoghossian (N)

Department of Stroke Medicine, Universit. Claude Bernard Lyon 1, CREATIS CNRS UMR 5220-INSERM U1206, INSA- Lyon, Hospices Civils de Lyon, France (N.N.).

Salvador Pedraza (S)

Department of Radiology, Institut de Diagnostic per la Image (IDI), Hospital Dr Josep Trueta, Institut d'Investigaci. Biomedica de Girona (IDIBGI), Parc Hospitalari Marti i Julia de Salt - Edifici M2, Girona, Spain (S.P.).

Claus Z Simonsen (CZ)

Department of Neurology, Aarhus University Hospital, Denmark (C.Z.S.).

Vincent Thijs (V)

Stroke Theme, Florey Institute of Neuroscience and Mental Health, University of Melbourne, Heidelberg, Victoria, Australia (V.T.).
Department of Neurology, Austin Health, Heidelberg, Victoria, Australia (V.T.).

Götz Thomalla (G)

Klinik und Poliklinik für Neurologie, Kopf- und Neurozentrum, University Medical Center Hamburg-Eppendorf, Germany (B.C., C.G., G.T.).

Robin Lemmens (R)

Department of Neurology, University Hospitals Leuven, Belgium (L.S., A.W., R.L.).
Department of Neurosciences, Experimental Neurology KU Leuven (L.S., A.W., R.L.), University of Leuven, Belgium.
Center for Brain and Disease Research, Laboratory of Neurobiology, VIB, Leuven, Belgium (L.S., A.W., R.L., J.B.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH